Literature DB >> 26629200

Age and the neuromuscular blockading effects of cisatracurium.

Jianrong Guo1, Xiaofang Zhou1, Xiaohong Yuan2, Huachun Shen1, Yiwei Zhang1.   

Abstract

PURPOSE: To investigate the influence of age on the neuromuscular blocking effect of cisatracurium.
METHODS: 90 patients with ASA I and II were assigned to the following groups according to their age: adults, children, and infants. Each group was subdivided into three subgroups according to the first dose of cisatracurium. Patients were administrated at a first dose of cisatracurium randomly, and their responses to train-of-four (TOF) stimulation were observed. When the same degree of the first response (T1) continuously repeats three times, the percentage of T1 inhibition was recorded, and the curve of dose-effect relationship and ED95 were calculated. A second dose of cisatracurium was then administrated (total volume 100 μg/kg). The recovery phase in each patient was observed upon T1 reaching the maximum blocking effect (100%).
RESULTS: Once the maximum blocking effect was reached, patients were intubated. There were 83 cases (92.2%) of patients with grade 1 and 7 (7.8%) patients with grade 2 intubating conditions. ED95 was 59.29, 55.88 and 45.39 μg/kg in adults, children, and infants, respectively. ED95 positively correlated with age. The clinical duration of neuromuscular blockade, effective action duration of neuromuscular blockade, and in vivo action duration of neuromuscular blockade in adults was longer than that in children (P<0.05), but shorter than in infants (P<0.05). However, there were no significant differences in the recovery index among groups (P>0.05).
CONCLUSION: Age influences the neuromuscular blocking effects of cisatracurium to a certain extent.

Entities:  

Keywords:  Cisatracurium; age; dose-effect relationship; recovery phase

Year:  2015        PMID: 26629200      PMCID: PMC4659088     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  18 in total

1.  Clinical validation of cardiac output measurements using femoral artery thermodilution with direct Fick in ventilated children and infants.

Authors:  S M Tibby; M Hatherill; M J Marsh; G Morrison; D Anderson; I A Murdoch
Journal:  Intensive Care Med       Date:  1997-09       Impact factor: 17.440

2.  High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children.

Authors:  Jieying Gao; Ting Yang; Mao Ye; Xiaoqing Zhang; Gang Tian; Qianna Zhen; Min Ding
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-02-23       Impact factor: 3.205

3.  Cisatracurium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children.

Authors:  Davinia Withington; Guillaume Ménard; France Varin
Journal:  Paediatr Anaesth       Date:  2011-01-12       Impact factor: 2.556

4.  Cisatracurium versus vecuronium: a comparative, double blind, randomized, multicenter study in adult patients under propofol/fentanyl/N2O anesthesia.

Authors:  C Melloni; P Devivo; C Launo; P Mastronardi; G P Novelli; E Romano
Journal:  Minerva Anestesiol       Date:  2006-05       Impact factor: 3.051

5.  Duration of action of vecuronium in infants and children anaesthetized without potent inhalation agents.

Authors:  I Kalli; O A Meretoja
Journal:  Acta Anaesthesiol Scand       Date:  1989-01       Impact factor: 2.105

6.  Pharmacodynamics and intubating conditions of cisatracurium in children during halothane and opioid anesthesia.

Authors:  C A Kenaan; R L Estacio; G B Bikhazi
Journal:  J Clin Anesth       Date:  2000-05       Impact factor: 9.452

7.  The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma.

Authors:  R M Welch; A Brown; J Ravitch; R Dahl
Journal:  Clin Pharmacol Ther       Date:  1995-08       Impact factor: 6.875

8.  The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.

Authors:  C A Lien; M R Belmont; A Abalos; L Eppich; S Quessy; M M Abou-Donia; J J Savarese
Journal:  Anesthesiology       Date:  1995-05       Impact factor: 7.892

9.  [Influences of age and gender on dose-response and recovery time-course of atracurium].

Authors:  F S Xue; X Liao; N He; Y M Zhang; G An
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2001-02

10.  The effect of low dose ketamine and priming of cisatracurium on the intubating condition and onset time of cisatracurium.

Authors:  Byung-Ryang Ahn; Sang-Hun Kim; Byung-Sik Yu; Kyung-Joon Lim; Jong-June Sun
Journal:  Korean J Anesthesiol       Date:  2012-10-12
View more
  1 in total

1.  Antagonist of Chrna1 prevents the pathogenesis of primary focal hyperhidrosis.

Authors:  Jian-Bo Lin; Nan-Long Lin; Xu Li; Ming-Qiang Kang
Journal:  Ann Clin Transl Neurol       Date:  2022-04-08       Impact factor: 5.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.